ABUS
Arbutus Biopharma Corporation
NASDAQ · Healthcare · Biotechnology · US
$5.15
+0.59%Year over year
Reported trailing growth
- Revenue
- +1078.8%
- EBITDA
- +372.1%
- EBIT
- +314.8%
- EPS
- +378.1%
- Free cash flow
- +59.1%
- Operating cash flow
- +59.1%
Forward estimates
Based on analyst estimates
- Revenue
- -97.8%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -28.8%
- EBITDA
- +51.7%
- EBIT
- +64.6%
- Net income
- +52.1%
- EPS
- +55.3%
- Free cash flow
- +39.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026